Morning Movers 06/15: (BVSN) (YPF) (BPAX) Higher; (IIVI) (DYAX) (IVN) Lower
Tweet
Share
E-mail
BroadVision (Nasdaq: BVSN) 22.3% HIGHER; trading higher amid Microsoft's (Nasdaq: MSFT) rumored buy of Yammer for $1 billion.
YPF (NYSE: YPF) 17% HIGHER; reports Carlos Slim has taken an 8.4% stake in the company
BioSante Pharma (Nasdaq: BPAX) 12.5% HIGHER; trading higher after Trimel received a No Objection Letter from Health Canada related to the Phase 2 study of Tefina.
II-VI (Nasdaq: IIVI) 12.3% LOWER; reduced its Q4 sales guidance from $137-$142 million to $135-$137 million and EPS from $0.27-$0.31 to $0.23-$0.25 cents. Reduced its FY12 sales guidance from $537-$540 million to $533-$535 million and EPS from $0.98-$1.02 to $0.94-$0.96.
Insmed, Inc. (Nasdaq: INSM) 10.6% HIGHER; traders cheering news of a filed registration with the U.S .Securities and Exchange Commission to sell, from time to time, up to $75 million of Common Stock, Preferred Stock, Warrants, Debt Securities, Units, or any combination thereof.
Dyax Corp. (Nasdaq: DYAX) 10.4% LOWER; reports the decision to discontinue the Companys Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis. This double-blind, placebo-controlled, randomized, dose-ranging study was designed to evaluate the efficacy and safety of ecallantide (10, 30, or 60 mg subcutaneous doses) compared to placebo, with a goal of enrolling 176 patients. The primary endpoint was the proportion of patients meeting a set of criteria indicating eligibility for discharge from the emergency department within 6 hours following study drug administration. Click here to see the full report.
ATP Oil & Gas (Nasdaq: ATPG) 8.7% HIGHER; traders buy the dip today following sharp downside over the last week. The stock fell 9 percent last Friday, 7 percent on both Monday and Tuesday, and another 12 percent on Wednesday. The stock has pushed over an important level at $4 this morning.
Ivanhoe Mines (NYSE: IVN) 8.7% LOWER; Ivanhoe Australia Limited announced the first shipment of copper-gold concentrate from the Osborne Copper-Gold Project in north-western Queensland. The 10,600 wet metric tonne shipment of concentrate has been loaded and is expected to leave Townsville on 15 June 2012. The shipment of concentrate to an Asian smelter contains copper valued at approximately A$15 million and gold valued at approximately A$5 million. The first shipment follows the pouring of the first bar of gold dore at Osborne (see Figure 1). This gold dore bar weighs approximately 9 kilograms.
YPF (NYSE: YPF) 17% HIGHER; reports Carlos Slim has taken an 8.4% stake in the company
BioSante Pharma (Nasdaq: BPAX) 12.5% HIGHER; trading higher after Trimel received a No Objection Letter from Health Canada related to the Phase 2 study of Tefina.
II-VI (Nasdaq: IIVI) 12.3% LOWER; reduced its Q4 sales guidance from $137-$142 million to $135-$137 million and EPS from $0.27-$0.31 to $0.23-$0.25 cents. Reduced its FY12 sales guidance from $537-$540 million to $533-$535 million and EPS from $0.98-$1.02 to $0.94-$0.96.
Insmed, Inc. (Nasdaq: INSM) 10.6% HIGHER; traders cheering news of a filed registration with the U.S .Securities and Exchange Commission to sell, from time to time, up to $75 million of Common Stock, Preferred Stock, Warrants, Debt Securities, Units, or any combination thereof.
Dyax Corp. (Nasdaq: DYAX) 10.4% LOWER; reports the decision to discontinue the Companys Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis. This double-blind, placebo-controlled, randomized, dose-ranging study was designed to evaluate the efficacy and safety of ecallantide (10, 30, or 60 mg subcutaneous doses) compared to placebo, with a goal of enrolling 176 patients. The primary endpoint was the proportion of patients meeting a set of criteria indicating eligibility for discharge from the emergency department within 6 hours following study drug administration. Click here to see the full report.
ATP Oil & Gas (Nasdaq: ATPG) 8.7% HIGHER; traders buy the dip today following sharp downside over the last week. The stock fell 9 percent last Friday, 7 percent on both Monday and Tuesday, and another 12 percent on Wednesday. The stock has pushed over an important level at $4 this morning.
Ivanhoe Mines (NYSE: IVN) 8.7% LOWER; Ivanhoe Australia Limited announced the first shipment of copper-gold concentrate from the Osborne Copper-Gold Project in north-western Queensland. The 10,600 wet metric tonne shipment of concentrate has been loaded and is expected to leave Townsville on 15 June 2012. The shipment of concentrate to an Asian smelter contains copper valued at approximately A$15 million and gold valued at approximately A$5 million. The first shipment follows the pouring of the first bar of gold dore at Osborne (see Figure 1). This gold dore bar weighs approximately 9 kilograms.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- Nanometrics (NANO) Issues Business Update, Reports FY23 Results
- Hempacco Co (HPCO) Receives Nasdaq Non-compliance Notice
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Carlos Slim, Morning MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
